Diagnostic Navigator Logo
  1. Diagnostic Navigator helps you guide patients along their biomarker testing journey.
  • Log in
  • REGISTER

Home

EGFR in Non–small Cell Lung Cancer
  • The Importance of Testing for EGFR Mutations at Initial Diagnosis in Metastatic NSCLC
  • The Multidisciplinary Team and EGFR Mutation Test Options at Initial Diagnosis
  • The Importance of Retesting for EGFR Mutations at Disease Progression
  • EGFR Mutation Test Options at Disease Progression
  • Sample Collection: An Important First Step
  • Read, Interpret, and Communicate Test Results
BRCA in Breast Cancer
  • Why Test for BRCA Mutations
  • Whom to Test: Guideline Recommendations
  • How to Test for BRCA Mutations
  • Interpreting Test Results
  • Informed Consent for BRCA Mutation Testing
  • Multidisciplinary Team Collaboration
BRCA in Ovarian Cancer
  • Why Test for BRCA Mutations
  • Whom to Test: Guideline Recommendations
  • How to Test for BRCA Mutations
  • Interpreting Test Results
  • Informed Consent for BRCA Mutation Testing
  • Multidisciplinary Team Collaboration
Find a Testing Lab Resources

EGFR in Non-small Cell Lung Cancer

The Importance of Testing for EGFR Mutations at Initial Diagnosis in Metastatic NSCLC The Multidisciplinary Team and EGFR Mutation Test Options at Initial Diagnosis The Importance of Retesting for EGFR Mutations at Disease Progression EGFR Mutation Test Options at Disease Progression Sample Collection: An Important First Step Read, Interpret, and Communicate Test Results

BRCA in Breast Cancer

Why Test for BRCA Mutations Whom to Test: Guideline Recommendations How to Test for BRCA Mutations Interpreting Test Results Informed Consent for BRCA Mutation Testing Multidisciplinary Team Collaboration

BRCA in Ovarian Cancer

Why Test for BRCA Mutations Whom to Test: Guideline Recommendations How to Test for BRCA Mutations Interpreting Test Results Informed Consent for BRCA Mutation Testing Multidisciplinary Team Collaboration

Find a Testing Lab

Resources

a a

Learn about how mutations in EGFR can affect patients with metastatic NSCLC

Learn more about the people involved in EGFR mutation testing as well as the diagnostics available to test at initial diagnosis

Understand how NSCLC tumors may adapt over time and the importance of retesting for EGFR mutations at disease progression

Review FDA-approved and CLIA-validated diagnostics available for EGFR mutation testing

Understand the sample types acceptable for EGFR mutation testing, including tissue- and plasma-based samples

Learn more about how to read an EGFR mutation test report, and review key communication points to discuss with your patients

On your mobile device, you will be able to access the content modules but not the Knowledge Checkpoints.

To test your knowledge and become a Diagnostic Navigator, please register or login using a desktop or tablet device.

 
You have been idle for 20 minutes. Session Expired!

Log in to your account

Login using
Email address:
*
Password:
*
Keep me logged in

  • Forgot Password

Back to top

  • Go to EGFRevolution Site
  • Contact Us
  • Visit AZOncologyID.com
  • |
  • Contact Us
  • |
  • Privacy Notice
  • |
  • Cookie Notice
  • |
  • Legal Statement
US-Flag

This site is intended for US Health Care Professionals only.

AstraZeneca Logo

©2019 AstraZeneca. All rights reserved. US-20811; US-24980 Last Updated 8/19